Celecoxib (Celebrex) and other COX-2 Selective Inhibitors
March 3, 2021
53,479
1,150
81
2.30%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Professor Dave Explains Episodes Around March 3, 2021
See what was published immediately before and after this episode.
5:12Now PlayingCelecoxib (Celebrex) and other COX-2 Selective Inhibitors
YouTube Description
as posted by the channelWe know that NSAIDs can inhibit both COX-1 and COX-2 enzymes. But these enzymes perform slightly different functions, and it seems that inhibition of COX-2 leads to the beneficial affects of NSAIDs while inhibition of COX-1 leads to the unwanted side effects. Well what if we could take advantage of slight discrepancies in the two active sites to inhibit only one enzyme and not the other? In fact it's been done! However, so far the results are not as promising as hoped. In fact, one such drug, Vioxx, was the subject of the largest drug recall in history. Let's get a closer look at this and other COX-2 selective inhibitors.
Script by Chris Hofmann
Watch the whole Pharmacology playlist
General Chemistry Tutorials
Organic Chemistry Tutorials
Biochemistry Tutorials
Biology/Genetics Tutorials
Anatomy & Physiology Tutorials
Biopsychology Tutorials
Microbiology/Infectious Diseases Tutorials
History of Drugs Videos
Immunology Tutorials
EMAIL► ProfessorDaveExplains@gmail.com
Check out "Is This Wi-Fi Organic?", my book on disarming pseudoscience!
Barnes and Noble
Book Depository
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.